中美突破性治疗药物制度实施效果的比较研究

文鑫, 田丽娟

中国新药杂志 ›› 2026, Vol. 35 ›› Issue (10) : 1032 -1039.

PDF (1546KB)
中国新药杂志 ›› 2026, Vol. 35 ›› Issue (10) : 1032 -1039. DOI: 10.20251/j.cnki.1003-3734.2026.10.004
新药述评与论坛

中美突破性治疗药物制度实施效果的比较研究

    文鑫, 田丽娟*
作者信息 +

A comparative study of the implementation effects of breakthrough therapeutic drug systems in China and the United States

    WEN Xin, TIAN Li-juan*
Author information +
文章历史 +
PDF (1582K)

摘要

目的: 借鉴美国突破性治疗药物(breakthrough therapy designation,BTD)制度的有益经验,为完善我国BTD制度提供建议和参考。方法: 通过对中美BTD制度的实施效果进行比较分析,揭示两国BTD制度的实施效果与差距。结果与结论: 中美BTD认定申请数量总体均呈增长趋势,但我国BTD认定率和认定获批率均显著低于美国,这可能与申请质量参差不齐和政策细化程度不足有关。我国BTD药物上市前临床开发时间较短,但审评时间较长,反映了两国药品监管机构在临床试验指导力度上的差异。在抗肿瘤药物临床试验设计方面,我国更倾向于单臂、非随机设计,以客观缓解率为主要终点;而美国试验设计则更为丰富与多元。此外,尚未有BTD中药获批上市。建议我国药品监管机构借鉴美国经验,制定BTD审评管理规范,加强审评人员的主导作用,设立跨学科团队,加强临床试验研制指导,提高研发及审评效率;同时,加强BTD认定药物叠加附条件批准上市后的监管,并推动BTD中药的申报与审批。医药企业应加强研发团队BTD法规和技能培训,提高BTD药物申请的质量,促进产品加快上市以满足患者临床需求。

Abstract

Objective: To draw on the useful experience of the breakthrough therapy designation (BTD) system in the United States (US) to provide suggestions and references for improving the BTD system in China. Methods: Through a comparative analysis of the implementation effects of the BTD systems in China and the US, the implementation effects and gaps of the BTD systems in the two countries were revealed. Results & Conclusion: The numbers of applications for BTD recognition in China and the US were generally on the rise, but the rates of BTD recognition and approval in China were significantly lower than those in the US, which may be related to the uneven quality of the applications and the lack of policy refinement. China's BTD drugs had a shorter pre-market clinical development time, but a longer review time, reflecting the difference in the strength of clinical trial guidance between the two countries' drug regulatory agencies. In terms of clinical trial design for antitumour drugs, China preferred single-arm, non-randomised design with objective remission rate as the primary endpoint; whereas the trial designs in the US were richer and more diverse. In addition, no BTD Chinese medicine has been approved for marketing. It is recommended that China's drug regulatory agencies learn from the US experience, formulate BTD review and management standards, strengthen the leading role of reviewers, set up interdisciplinary teams, strengthen the guidance of clinical trial development and improve the efficiency of research and development and review; at the same time, strengthen the supervision of BTD-recognised medicines after superimposed conditional approval for listing, and promote the declaration and approval of BTD traditional Chinese medicines. Pharmaceutical companies should strengthen the training of R&D teams on BTD regulations and skills, improve the quality of BTD drug applications, and promote the accelerated marketing of products to meet patients' clinical needs.

关键词

突破性治疗药物 / 药品注册 / 实施效果

Key words

breakthrough therapy designation / drug registration / implementation effect

引用本文

引用格式 ▾
文鑫, 田丽娟. 中美突破性治疗药物制度实施效果的比较研究[J]. 中国新药杂志, 2026, 35(10): 1032-1039 DOI:10.20251/j.cnki.1003-3734.2026.10.004

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1] 袁利佳, 汪小燕, 杨志敏, 等. 突破性治疗药物程序在药品注册体系中的作用及展望[J]. 中国药事, 2022, 36(9): 973-983.
[2] LUO XX, QIAN F, YANG LN, et al. Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020-2022[J]. Drug Discov Today, 2022, 27(12): 103370.
[3] 胡一琳, 赵晓佩, 马美英, 等. 美国突破性治疗(BTD)程序实施对我国的启示[J]. 卫生软科学, 2023, 37(12): 85-88.
[4] 国家药品监督管理局. 2020年度药品审评报告[EB/OL].(2021-06-21)[2025-04-19].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20210621142436183.html.
[5] 国家药品监督管理局. 2021年度药品审评报告[EB/OL].(2022-06-01)[2025-04-19].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20220601110541120.html.
[6] 国家药品监督管理局. 2022年度药品审评报告[EB/OL].(2023-09-06)[2025-04-19].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20230906163722146.html.
[7] 国家药品监督管理局. 2023年度药品审评报告[EB/OL].(2024-02-04)[2025-04-19].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20240204154334141.html.
[8] 国家药品监督管理局药品审评中心. 2024年度药品审评报告[EB/OL].(2025-03-18)[2025-04-19].https://www.cde.org.cn/main/news/viewInfoCommon/54538c67b7e764fc51666567fc620241.
[9] Center for Drug Evaluation and Research. Breakthrough Therapy Approvals[EB/OL].(2025-01-13)[2025-04-19].https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals.
[10] Center for Biologics Evaluation and Research. CBER Approvals for Breakthrough Therapy Designated Drugs[EB/OL].(2025-02-14)[2025-04-19].https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/cber-approvals-breakthrough-therapy-designated-drugs.
[11] Center for Drug Evaluation and Research. Breakthrough Therapy Designation Requests[EB/OL].(2025-01-13)[2025-04-19].https://www.fda.gov/drugs/ind-activity/breakthrough-therapy-designation-requests.
[12] Center for Biologics Evaluation and Research. CBER Breakthrough Therapy Designation Requests[EB/OL].(2025-02-14)[2025-04-19].https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/cber-breakthrough-therapy-designation-requests.
[13] 国家药品监督管理局政务服务门户. 药品批件发布信息[EB/OL].(2024-12-31)[2025-04-19].https://www.nmpa.gov.cn/zwfw/zwfwpjfbzs/pjfbzsyp/index.html.
[14] 国家药品监督管理局药品审评中心. 上市药品信息[EB/OL].(2024-12-31)[2025-04-19].https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d.
[15] Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs[EB/OL].(2024-12-31)[2025-04-19].https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
[16] World Health Organization. International Classification of Diseases 11th Revision[EB/OL].(2024-12-31)[2025-04-19].https://icd.who.int/en/.
[17] 党子悦, 郭冬梅. 我国药品加快上市注册程序的注册情况分析[J]. 中国药事, 2023, 37(7): 735-742.
[18] SHEA M, OSTERMANN L, HOHMAN R, et al. Impact of breakthrough therapy designation on cancer drug development[J]. Nat Rev Drug Discov, 2016, 15: 152.
[19] LUO XX, DU X, LV XF, et al. Clinical benefit, price, and regulatory approval of cancer drugs granted breakthrough therapy designation in China, 2020-2024[J]. JAMA Netw Open, 2024, 7(10): e2439080.
[20] 王婧璨, 温宝书, 陈成立. 美国新药临床试验期间沟通交流机制简介与思考[J]. 中国新药杂志, 2020, 29(11): 1222-1226.
[21] 邹丽敏, 杜瑜, 齐玥丽, 等. 抗肿瘤新药突破性治疗药物认定的标准及考虑[J]. 中国临床药理学杂志, 2021, 37(11): 1471-1475.
[22] 宋茵茵, 徐文峰, 胡欣, 等. 我国附条件批准上市抗肿瘤药物探讨[J]. 中国药业, 2022, 31(19): 12-18.
[23] 孙一卜, 郝恣若, 陈玉文. 中国临床试验数据被国际接受的难点及对策[J]. 中国新药杂志, 2025, 34(23): 2486-2489.
[24] 广东省药学会, 李晓彦, 邹燕琴, 等. 药物临床试验伦理审查·广东共识(2025年版)[J]. 今日药学, 2025, 35(11): 801-805.
[25] 江旻, 刘晓红, 房虹, 等. 药物直达临床试验参与者模式在临床试验中实施的专家共识[J]. 中国新药杂志, 2025, 34(21): 2306-2315.
[26] 袁林, 邵明立. 美国突破性治疗及其对我国新药审评的启示[J]. 中国新药杂志, 2017, 26(1): 1-6.
[27] 吴晨悦, 韩炜, 曲建博, 等. 2020年以来中药创新药批准上市情况分析及思考[J]. 中国新药杂志, 2025, 34(22): 2358-2365.
[28] 孙青山, 姚佳, 李锴诺. 中药专利申请中的实验数据审查问题研究[J]. 中国新药杂志, 2025, 34(22): 2372-2377.

AI Summary AI Mindmap
PDF (1546KB)

534

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉